哮喘患者GLCCI1基因检测指导吸入糖皮质激素的安全性用药效果
Effect of inhaled corticosteroids guided by GLCCI1 gene detection on treatment of patients with asthma
-
摘要: 目的 探讨哮喘患者GLCCI1基因检测指导吸入糖皮质激素安全性用药的临床价值.方法 选取80例哮喘患者,依据GLCCI1基因检测结果分为野生型等位基因组(n=64)以及突变型等位基因组(n=16),均采用布地奈德气雾剂治疗,比较2组患者临床疗效.结果 野生型等位基因组患者治疗总有效率92.2％,不良反应发生率7.8％,而突变型等位基因组患者治疗总有效率75％,不良反应发生率25％,差异有统计学意义(P＜0.05).2组患者FEV1、FEV1/FVC、FVC、PEF比较,差异有统计学意义(P＜0.05).结论 GLCCI1基因检测可显著提高吸入糖皮质激素治疗效果并降低不良反应发生率.Abstract: Objective To explore the clinical value of GLCCI1 gene detection in guiding administration of inhaled corticosteroids in patients with asthma.Methods Eighty asthma patients were divided into wild type allele group (n =64) and mutant type allele group (n =16) according to GLCCI1 gene detection.Both groups were treated with budesonide aerosol,and the clinical effect was compared between two groups.Results In wild type allele group,the total effective rate was 92.2％ and the incidence rate of adverse reaction was 7.8％,which were significantly better than 75.0％ and 25.0％ in mutant type allele group (P ＜ 0.05).There were significant differences in FEV1,FEV/FVC ratio,FVC and PEF between two groups (P ＜ 0.05).Conclusion The GLCCI1 gene detectiou can significantly improve the effect of inhaled corticosteroids and reduce the incidence rate of adverse reactions.
下载: